Lupin Receives FDA Approval for Generic Potassium Chloride Oral Solution

Pharma major Lupin announced that it has received approval for its Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10 percent) and 40 mEq/15 mL (20 percent) from the United States Food and Drug Administration (FDA) to market a generic version of Genus Lifesciences, Inc.’s Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10 percent) and 40 mEq/15 mL (20 percent). Lupin’s Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10 percent) and 40 mEq/15 mL (20 percent) is the generic version of Genus’ Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10 percent) and 40 mEq/15 mL (20 percent). It is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods and/or diuretic dose reduction are insufficient. Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10 percent) and 40 mEq/15 mL (20 percent) had annual sales of approximately USD 184.95 million in the US (IQVIA MAT June 2018). – Medical Buyer Bureau